TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35981838
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline hydration (control)
Study: 33030846
Drug: Yoga (performed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga (performed twice a week for ten sessions)
Study: 35546299
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) with 915 nm diode laser (1.5 W, duty cycle of 60%, energy density of 72 J cm²)
Study: 33437904
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning algorithm using a combination of IL-2, MIG/CCL9, RANTES/CCL5, SCF, and TRAIL
Study: 32985237
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nutritional supplementation and resistance exercise
Study: 34142184
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of autologous micro-fragmented adipose tissue
Study: 32319087
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg rocuronium iv
Study: 32319087
Drug: 0.30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/kg rocuronium iv
Study: 32319087
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no additional drug administration)
Study: 33681744
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam (5 mg)
Study: 35719707
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg twice a day)
Study: 35719707
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (500 mg twice a day)
Study: 35719707
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg microcrystalline cellulose twice a day)
Study: 32520623
Drug: KBP-5074 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBP-5074 0.25 mg
Study: 32520623
Drug: KBP-5074 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBP-5074 0.5 mg
Study: 32520623
Drug: KBP-5074 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBP-5074 (both doses)
Study: 32197408
Drug: HD plus
Normalized name: Endal-HD Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD plus De Simone Formulation probiotic blend
Study: 32022771
Drug: Aspirin in
Normalized name: Non-Aspirin Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in patients with previous percutaneous coronary intervention
Study: 32022771
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo for both aspirin and clonidine)
Study: 35081564
Drug: Combination pulsed-dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pulsed-dye laser (PDL) and nonablative fractional laser (NAFL)
Study: 34836240
Drug: L-carnitine tartrate
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine tartrate at 50 µM and creatine monohydrate at 0.5 µM combined
Study: 34836240
Drug: Creatine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine with LMP formulation at 51 mg/kg
Study: 34836240
Drug: LMP formulated
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMP formulated L-carnitine at 500 mg with LMP formulated creatine at 100, 200, or 500 mg
Study: 33291975
Drug: Meloxicam intravenous
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam intravenous (30 mg once daily)
Study: 33291975
Drug: Meloxicam intravenous
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam intravenous
Study: 33371107
Drug: Qiangji Jianli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiangji Jianli Capsule (QJC)
Study: 33691519
Drug: Parent ratings
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent ratings of child functioning before treatment
Study: 34020837
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive pressure treatment for OSA
Study: 34020837
Drug: Best treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best treatment of each disease separately and recognition and treatment of comorbidities
Study: 32057716
Drug: Calorie restriction
Normalized name: Resurrection Lily Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie restriction (CR) - 70% of energy needs daily
Study: 35130863
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (intraoperative warming set to 38 °C)
Study: 34684312
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of L-citrulline
Study: 32408390
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg once a day)
Study: 32408390
Drug: Mirabegron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (50 mg once a day)
Study: 35655485
Drug: Control (Conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Conservative Treatment)
Study: 35799169
Drug: Rubus idaeus
Normalized name: RUBUS IDAEUS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubus idaeus leaf extract 400 mg
Study: 35799169
Drug: Rubus idaeus
Normalized name: RUBUS IDAEUS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubus idaeus leaf extract 200 mg
Study: 34133348
Drug: Edaravone (EDA)
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Edaravone (EDA) administered intravenously 30 min before surgery
Study: 32916151
Drug: High Fructose
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Fructose Corn Syrup (HFCS) (25% of energy requirements)
Study: 37270883
Drug: Intracoronary tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary tirofiban (25 mcg/kg infused over 5 minutes followed by 0.15 mcg/kg/min for 12-18 hours)
Study: 38821658
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no laser treatment)
Study: 32314038
Drug: Obinutuzumab-chemotherapy
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab-chemotherapy
Study: 33888067
Drug: Aripiprazole (1-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (1-15 mg/day)
Study: 33484095
Drug: Boost articulation
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost articulation therapy (BArT)
Study: 33039958
Drug: Combined immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunotherapy (anti-PD-1 antibody) and antiangiogenic therapy
Study: 32404342
Drug: Canakinumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (4 mg/kg, maximum 300 mg subcutaneous every 4 weeks)
Study: 39418460
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure (PE) therapy
Study: 33419674
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine therapy (Jinhaoartemisia antipyretic granules and Huoxiangzhengqi oral liquids)
Study: 34402024
Drug: Trans-resveratrol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-resveratrol (500 mg orally once daily for 52 weeks)
Study: 32747036
Drug: Low-dose estradiol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estradiol (0.5 mg) / dydrogesterone (2.5 mg)
Study: 35647831
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise plus metformin (AEM)
Study: 35647831
Drug: Metformin only
Normalized name: Metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin only (M)
Study: 34213061
Drug: Isatuximab in
Normalized name: isatuximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab in combination with pomalidomide and dexamethasone (IsaPd)
Study: 34578808
Drug: Sil-Q1 (SQ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sil-Q1 (SQ; silk peptide) 7.5 g for 8 weeks
Study: 33764994
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus fatty acids (Intralipid plus heparin)
Study: 33764994
Drug: Saline/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/heparin
Study: 36346039
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: isotretinoin 0.5‐1 mg/kg/day for 24 weeks
Study: 36346039
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: isotretinoin 0.25‐0.4 mg/kg/day for 24 weeks
Study: 36346039
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: isotretinoin 0.5‐0.7 mg/kg/day for 1 week out of every 4 weeks for 24 weeks
Study: 32613329
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (60 mg of elemental iron in combined iron–folic acid pills) from 12 weeks of gestation until delivery
Study: 34433548
Drug: Selective laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective laser trabeculoplasty (SLT): approximately 100 shots, 3 ns, 400 µm spot size administered 360 degrees at the limbus using any gonioscopy lens, energy 0.3‐2.6 mJ.
Study: 34748164
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of long-term antidepressant medication
Study: 34748164
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance antidepressants
Study: 33504262
Drug: Topical EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EPO and standard-of-care (SOC)
Study: 33504262
Drug: Topical EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EPO and SOC
Study: 33504262
Drug: Topical EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EPO
Study: 33744327
Drug: GDC-0214 15
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-0214 15 mg QD
Study: 33744327
Drug: GDC-0214 15
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-0214 15 mg twice daily
Study: 32140784
Drug: Eldecalcitol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol (0.75 μg)
Study: 32140784
Drug: Alfacalcidol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1.0 μg)
Study: 36075773
Drug: Remimazolam at
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam at doses of 0.25–0.33 mg kg−1 for patients aged <40
Study: 36075773
Drug: Remimazolam at
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam at doses of 0.19–0.25 mg kg−1 for patients aged 40–60
Study: 36075773
Drug: Remimazolam at
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam at doses of 0.14–0.19 mg kg−1 for patients aged 60–80
Study: 33481053
Drug: injectable platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: injectable platelet-rich fibrin (i-PRF) injected into the mucosa on the buccal and palatal aspects of the intervention sides, repeated one month later
Study: 37275963
Drug: Ribociclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib plus endocrine therapy (ET)
Study: 33149768
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus endocrine therapy (ET)
Study: 36378778
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (extended-release niacin and placebo)
Study: 32798376
Drug: Diabetic patients
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic patients (gender, age, treatment type)
Study: 32798376
Drug: Gender, age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender, age, and treatment type
Study: 32354652
Drug: Ectoin® Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ectoin® Eye Spray (EES09)
Study: 32354652
Drug: Tears Again®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tears Again® Eye Spray (TA)
Study: 34756796
Drug: Standard hand
Normalized name: ALCOHOL 48 mL in 60 mL TOPICAL LIQUID [Silver Standard Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hand therapy plus workplace-based educational intervention (Working Hands-ED) for 12 weeks
Study: 34756796
Drug: Standard hand
Normalized name: ALCOHOL 48 mL in 60 mL TOPICAL LIQUID [Silver Standard Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hand therapy for 12 weeks
Study: 34996108
Drug: IV dex
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dex (1ug/kg) with propofol (1 mg/kg)
Study: 34996108
Drug: IV propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV propofol (1 mg/kg)
Study: 35367070
Drug: AS01B‐adjuvanted HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS01B‐adjuvanted HBV surface antigen vaccine
Study: 32163508
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and GS‐561937 (FPI) combination therapy started at 3 days post infection
Study: 32163508
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and GS‐561937 (FPI) combination therapy started at 5 days post infection
Study: 32163508
Drug: Ibuprofen alone
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen alone started on day 3
Study: 32163508
Drug: FPI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPI with ibuprofen started on day 3
Study: 35219277
Drug: Sarilumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 400 mg
Study: 33779203
Drug: WSWS2-L (long
Approvals — FDA: no, EMA: no, PMDA: no
Description: WSWS2-L (long version with 19 items)
Study: 35670658
Drug: Hyperinsulinemic-hypoglycemic phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperinsulinemic-hypoglycemic phase (2.5 mmol/L) followed by recovery to hyperglycemia (20 mmol/L)
Study: 35670658
Drug: Recovery phase
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery phase in hyperglycemia (20 mmol/L)
Study: 35670658
Drug: Recovery phase
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery phase in euglycemia (5.0-8.0 mmol/L)
Study: 36215226
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose vitamin D (800 IU/day)
Study: 36215226
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose vitamin D (3200 IU/day)
Study: 33727268
Drug: Standard maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard maintenance therapy
Study: 35193803
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.5 g/L tranexamic acid (TXA)
Study: 33421230
Drug: Oral sucrosomial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrosomial iron (SI) 28 mg daily for 3 months
Study: 33964855
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg vitamin D3/d
Study: 33637605
Drug: D-allulose 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-allulose 7.5 g
Study: 33637605
Drug: D-allulose 10
Normalized name: D & C YELLOW #10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-allulose 10 g
Study: 32938620
Drug: Palbociclib 200
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort A)
Study: 32938620
Drug: Palbociclib 200
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort B1)
Study: 32938620
Drug: Palbociclib 200
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort B2)
Study: 32938620
Drug: Palbociclib in
Normalized name: Product containing palbociclib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib in combination with trastuzumab
Study: 34349503
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of regorafenib (40 mg)
Study: 34349503
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of regorafenib (Stivarga®, 40 mg)
Study: 34349503
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of regorafenib (40 mg)
Study: 33784411
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids (INCS) - triamcinolone acetonide (220 µg)
Study: 32810089
Drug: Kangaroo mother
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo mother care therapy
Study: 36417057
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg EOD
Study: 36417057
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg EOD (after switching from placebo)
Study: 32991399
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine + diet
Study: 32347777
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (IIV3) administered intradermally or intramuscularly
Study: 34871580
Drug: 1.62% transdermal
Normalized name: Androgel 1.62% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% transdermal testosterone gel
Study: 34871580
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo gel
Study: 35543281
Drug: RSVpreF 60
Normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF 60 µg with Al(OH)3
Study: 35543281
Drug: RSVpreF 60
Normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF 60 µg with CpG/Al(OH)3
Study: 35543281
Drug: RSVpreF 120
Normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF 120 µg with Al(OH)3
Study: 35543281
Drug: RSVpreF 120
Normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF 120 µg with CpG/Al(OH)3
Study: 35543281
Drug: RSVpreF 240
Normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF 240 µg with Al(OH)3
Study: 35543281
Drug: RSVpreF 240
Normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF 240 µg with CpG/Al(OH)3
Study: 35543281
Drug: RSVpreF 240
Normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF 240 µg unadjuvanted
Study: 35543281
Drug: RSVpreF 240
Normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF 240 µg with CpG/Al(OH)3 (month 0,2 cohort)
Study: 35543281
Drug: High-dose seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose seasonal inactivated influenza vaccine (SIIV)
Study: 35543281
Drug: RSVpreF formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF formulations
Study: 33148479
Drug: Abemaciclib 150
Normalized name: abemaciclib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 150 mg plus Tamoxifen 20 mg (A+T)
Study: 33148479
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg plus prophylactic loperamide (A-200)
Study: 33148479
Drug: Abemaciclib 150
Normalized name: abemaciclib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 150 mg every 12 hours (A-150)
Study: 36219407
Drug: Paroxetine 40
Normalized name: PARoxetine 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 40 mg daily plus Oxycodone 10 mg
Study: 36219407
Drug: Quetiapine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (100 mg to 400 mg) plus Oxycodone 10 mg
Study: 36219407
Drug: Paroxetine 40
Normalized name: PARoxetine 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 40 mg daily
Study: 36219407
Drug: Quetiapine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (100 mg to 400 mg)
Study: 36219407
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Oxycodone 10 mg
Study: 33941921
Drug: Durvalumab in
Normalized name: durvalumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab in combination with FGFR inhibitors
Study: 33941921
Drug: Durvalumab in
Normalized name: durvalumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab in combination with PARP inhibitors
Study: 33941921
Drug: Durvalumab in
Normalized name: durvalumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab in combination with TORC1/2 inhibitors
Study: 38430375
Drug: Durvalumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab monotherapy
Study: 32469260
Drug: Beetroot extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot extract (600 mg in capsule)